JP2009515814A5 - - Google Patents

Download PDF

Info

Publication number
JP2009515814A5
JP2009515814A5 JP2008503187A JP2008503187A JP2009515814A5 JP 2009515814 A5 JP2009515814 A5 JP 2009515814A5 JP 2008503187 A JP2008503187 A JP 2008503187A JP 2008503187 A JP2008503187 A JP 2008503187A JP 2009515814 A5 JP2009515814 A5 JP 2009515814A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
amino
membered
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008503187A
Other languages
English (en)
Japanese (ja)
Other versions
JP5142981B2 (ja
JP2009515814A (ja
Filing date
Publication date
Priority claimed from US11/386,271 external-priority patent/US20060216288A1/en
Application filed filed Critical
Publication of JP2009515814A publication Critical patent/JP2009515814A/ja
Publication of JP2009515814A5 publication Critical patent/JP2009515814A5/ja
Application granted granted Critical
Publication of JP5142981B2 publication Critical patent/JP5142981B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008503187A 2005-03-22 2006-03-22 抗ｅｇｆｒ抗体およびｖｅｇｆｒ阻害剤を含む、癌の治療のための組み合わせ Expired - Fee Related JP5142981B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66438105P 2005-03-22 2005-03-22
US60/664,381 2005-03-22
US11/386,271 2006-03-21
US11/386,271 US20060216288A1 (en) 2005-03-22 2006-03-21 Combinations for the treatment of cancer
PCT/US2006/010582 WO2006102504A2 (en) 2005-03-22 2006-03-22 Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors

Publications (3)

Publication Number Publication Date
JP2009515814A JP2009515814A (ja) 2009-04-16
JP2009515814A5 true JP2009515814A5 (https=) 2009-05-28
JP5142981B2 JP5142981B2 (ja) 2013-02-13

Family

ID=37035437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008503187A Expired - Fee Related JP5142981B2 (ja) 2005-03-22 2006-03-22 抗ｅｇｆｒ抗体およびｖｅｇｆｒ阻害剤を含む、癌の治療のための組み合わせ

Country Status (7)

Country Link
US (2) US20060216288A1 (https=)
EP (1) EP1915151B1 (https=)
JP (1) JP5142981B2 (https=)
AU (1) AU2006226897B2 (https=)
CA (1) CA2600195C (https=)
MX (1) MX2007011545A (https=)
WO (1) WO2006102504A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR20070121754A (ko) * 2005-03-21 2007-12-27 마커사이트, 인코포레이티드 질환 또는 상태의 치료를 위한 약물 송달 시스템
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
JP2010508277A (ja) * 2006-11-01 2010-03-18 ジョージ メイソン インテレクチュアル プロパティーズ，インコーポレイテッド オブ フェアファックス，バージニア 癌を検出および抑制するための方法
CN101675075B (zh) 2007-03-01 2014-06-18 西福根有限公司 重组抗表皮生长因子受体抗体组合物
US8609640B2 (en) 2007-07-25 2013-12-17 Eisai, Inc. Multikinase inhibitors for use in the treatment of cancer
WO2009023877A2 (en) * 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
FR2921657A1 (fr) * 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
AU2008318690B2 (en) * 2007-10-29 2015-08-13 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
RU2601892C2 (ru) * 2008-03-06 2016-11-10 Дженентек, Инк. Комбинированная терапия антагонистами с-мет и egfr
EP2260056A1 (en) * 2008-03-06 2010-12-15 Genentech, Inc. Combination therapy with c-met and her antagonists
US20120035183A1 (en) * 2008-03-19 2012-02-09 Gilmer Tona M Cancer Treatment Method
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
JP6013359B2 (ja) 2010-12-17 2016-10-25 ノバルティス アーゲー 組合せ
WO2012099968A1 (en) * 2011-01-19 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating skin cancer associated diseases
JP2014504638A (ja) * 2011-02-01 2014-02-24 グラクソスミスクライン インテレクチュアル プロパティ リミテッド 組合せ
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
WO2013173255A2 (en) 2012-05-17 2013-11-21 Sorrento Therapeutics Inc. Antigen binding proteins that bind egfr
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US20050241006A1 (en) * 1995-04-27 2005-10-27 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
JP3789066B2 (ja) * 1999-12-08 2006-06-21 三菱電機株式会社 液晶表示装置
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US8725620B2 (en) * 2000-07-10 2014-05-13 Nobuyoshi Morimoto System and method for negotiating improved terms for products and services being purchased through the internet
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
US6630500B2 (en) * 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2466762A1 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
CN1625602A (zh) * 2002-03-13 2005-06-08 霍夫曼-拉罗奇有限公司 选择药物敏感性决定因子的方法和利用所选择的因子预测药物敏感性的方法
WO2003099205A2 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
CA2555306A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody

Similar Documents

Publication Publication Date Title
JP2009515814A5 (https=)
CA2600195A1 (en) Combinations for the treatment of cancer
Schenone et al. Antiangiogenic agents: an update on small molecule VEGFR inhibitors
KR101546693B1 (ko) 치환된 퀴놀린 화합물 및 그 사용 방법
CN103857288B (zh) 作为激酶抑制剂的氨基-喹啉
JP6997876B2 (ja) Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
JP2022501431A (ja) Ｓｒｃホモロジー−２ホスファターゼ阻害剤としての縮合三環式環誘導体
MX2010012290A (es) Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
JP5852678B2 (ja) 抗腫瘍剤の効果増強剤
JP2019518767A (ja) Ｃｘｃｒ４阻害剤およびその使用
JP2013528204A5 (https=)
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
HRP20220990T1 (hr) 3-supstituirane propionske kiseline kao inhibitori alfa v integrina
JP2019518768A (ja) Ｃｘｃｒ４阻害剤およびその使用
JP2006520805A5 (https=)
JP2016525076A5 (https=)
TW201542528A (zh) 喹啉衍生物
JP2014513110A5 (https=)
JP2018531983A (ja) タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
JP2015524472A5 (https=)
JP2015518894A5 (https=)
JP2017505762A5 (https=)
JP6751212B2 (ja) 抗腫瘍剤
JP2014518544A5 (https=)
JP2018501315A5 (https=)